We decided to consider the HER2-Neu molecular aspect in our cells since it has been described that human CRC are positive for HER2 staining [35] and that activating mutations and amplifications of ErbB2 account for 7% of cases (Cancer Genome Atlas Network). The gene discussed is ERBB2; the disease is colorectal carcinoma.